Drug firms fined in Medicaid fraud
From Times Wire Reports
A Montgomery jury found that two major pharmaceutical companies defrauded the state in a long-running Medicaid drug-pricing scheme and ordered the firms to pay more than $114 million in damages.
The jury found that Glaxo- SmithKline should pay $80.8 million in compensatory damages and that Novartis should pay about $33.7 million in similar damages.
It declined to order punitive damages.
The companies were deciding whether to appeal.
